In vitro evaluation of cefodizime, cefuroxime, ceftriaxone against respiratory pathogens.
The in vitro activity of cefodizime and two comparative cephalosporins, cefuroxime and ceftriaxone were studied against respiratory pathogens. MIC90s of cefodizime were 0.06-0.512 microgram/ml for Streptococcus pneumoniae, Moraxella catarrhalis and Haemophilus influenzae. MIC50s of cefodizime for Klebsiella pneumoniae and Staphylococcus aureus isolates were 2 micrograms/ml and 8 micrograms/ml respectively. Cefuroxime and ceftriaxone at a concentration of 2 micrograms/ml and 1 microgram/ml inhibited 50% of Klebsiella pneumoniae and 50% of Staphylococcus aureus strains studied respectively. Cefodizime inhibited many of the important respiratory pathogens and can be suggested as an active antimicrobial agent for respiratory tract infections.
Paniara
O
O
Department of Microbiology, Evangelismos Hospital, Athens, Greece.
Platsouka
E
E
Dimopoulou
H
H
Constantoulaki
S
S
D002439:Cefotaxime / Q000031:analogs & derivatives* / Q000494:pharmacology; D002443:Ceftriaxone / Q000494:pharmacology*; D002444:Cefuroxime / Q000494:pharmacology*; D006192:Haemophilus Infections / Q000382:microbiology; D006193:Haemophilus influenzae / Q000187:drug effects; D006801:Humans; D007710:Klebsiella Infections / Q000382:microbiology; D007711:Klebsiella pneumoniae / Q000187:drug effects; D008826:Microbial Sensitivity Tests; D001936:Moraxella catarrhalis / Q000187:drug effects; D016870:Neisseriaceae Infections / Q000382:microbiology; D011008:Pneumococcal Infections / Q000382:microbiology; D012141:Respiratory Tract Infections / Q000382:microbiology*; D013203:Staphylococcal Infections / Q000382:microbiology; D013211:Staphylococcus aureus / Q000187:drug effects; D013296:Streptococcus pneumoniae / Q000187:drug effects
D002443:Ceftriaxone; D002439:Cefotaxime; D002444:Cefuroxime; C033356:cefodizime